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Abstract 
Background: Advances in multi‑modality treatment of locally advanced rectal cancer (LARC) have resulted in low 
local recurrence rates, but around 30% of patients will still die from distant metastatic disease. In parallel, there is 
increasing recognition that with radiotherapy and systemic treatment, some patients achieve a complete response 
and may avoid surgical resection, including in many cases, the need for a permanent stoma. Extended neoadjuvant 
regimes have emerged to address these concerns. The inclusion of immunotherapy in the neoadjuvant setting has 
the potential to further enhance this strategy by priming the local immune microenvironment and engaging the 
systemic immune response.
Methods: PRIME‑RT is a multi‑centre, open label, phase II, randomised trial for patients with newly diagnosed LARC. 
Eligible patients will be randomised to receive either: short course radiotherapy (25 Gray in 5 fractions over one week) 
with concomitant durvalumab (1500 mg administered intravenously every 4 weeks), followed by FOLFOX (85 mg/m2 
oxaliplatin, 350 mg folinic acid and 400 mg/m2 bolus 5‑fluorouracil (5‑FU) given on day 1 followed by 2400 mg/m2 
5‑FU infusion over 46–48 h, all administered intravenously every 2 weeks), and durvalumab, or long course chemora‑
diotherapy (50 Gray to primary tumour in 25 fractions over 5 weeks with concomitant oral capecitabine 825 mg/m2 
twice per day on days of radiotherapy) with durvalumab followed by FOLFOX and durvalumab. The primary endpoint 
is complete response rate in each arm. Secondary endpoints include treatment compliance, toxicity, safety, overall 
recurrence, proportion of patients with a permanent stoma, and survival. The study is translationally rich with collec‑
tion of bio‑specimens prior to, during, and following treatment in order to understand the molecular and immuno‑
logical factors underpinning treatment response. The trial opened and the first patient was recruited in January 2021. 
The main trial will recruit up to 42 patients with LARC and commence after completion of a safety run‑in that will 
recruit at least six patients with LARC or metastatic disease.
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Background
Locally advanced rectal cancer (LARC), defined as 
stage II or stage III disease, constitutes up to one third 
of rectal tumours at diagnosis [1]. Treatment of LARC 
requires a multi-modality approach because surgical 
resection alone results in unacceptably high rates of 
local recurrence [2]. Radiotherapy is the main thera-
peutic modality currently used prior to surgery, deliv-
ered either as short course (5 × 5 Gray (Gy) over one 
week) (SCRT) or as long course radiotherapy with 
concurrent fluoropyrimidine chemotherapy (45–50 Gy 
over 5  weeks) (LCRT) [3, 4]. Leaving a ‘gap’ following 
radiotherapy allows for maturation of tumour regres-
sion and improves down-staging [5–7]. Increasingly, 
cytotoxic chemotherapy is being delivered in this gap, 
primarily to treat micro-metastatic disease and reduce 
distant recurrence [8, 9]. This strategy shows improved 
compliance and tolerability, and improved response 
rates compared to chemotherapy delivered in the adju-
vant setting [10–12], even with intensification of the 
chemotherapy regimen [12].
Using this approach of sequential radiotherapy and 
chemotherapy prior to surgery, also known as total 
neoadjuvant treatment, some patients achieve a clinical 
complete response (cCR) to treatment and if monitored 
carefully, a select number of these good responders can 
avoid surgery altogether. The evaluation of cCR is usu-
ally performed at the end of treatment and defined as 
the absence of clinically detectable tumour using radio-
logical evidence, clinical examination and endoscopic 
appearances [13]. Reports suggest that the proportion 
of patients achieving cCR after chemoradiotherapy in 
the order of around 15% [14, 15]. Pathological complete 
response (pCR) is confirmation of no viable tumour at 
resection for patients who do proceed to surgery [16]. 
Published series have demonstrated similar disease free 
survival (DFS) and overall survival (OS) for patients 
who have organ preservation after achieving a cCR 
compared to those who undergo surgery [17, 18], with 
3 year colostomy free survival of up to 74% [18]. Unfor-
tunately, approximately 20% of patients do not achieve 
any down-staging and, whilst the majority of patients 
have some response, most will still require surgery 
[15, 19, 20]. Given that only a minority of patients are 
achieving organ preservation with current treatments, 
intensification of neoadjuvant therapies is a primary 
research goal in rectal cancer [21].
There is a strong rationale for selecting immune check-
point blockade as a candidate therapy for treatment 
intensification in this context. Previous use of immuno-
therapy in colorectal cancer has been mainly limited to 
the metastatic setting, where good responses are seen 
particularly in patients with deficiency in mismatch 
repair (MMR) proteins within the tumour [22–24]. 
Although MMR deficiency is only detected in a minority 
of patients with LARC, the neoadjuvant setting provides 
an opportunity to evaluate this treatment in both MMR 
proficient, as well as MMR deficient LARC. Specifically, 
DNA damaging treatments used in the neoadjuvant set-
ting such as radiotherapy [25] and chemotherapy [26, 27] 
induce cellular damage and the resulting antigen expo-
sure can incite lymphocytic responses. In this respect, 
radiotherapy and chemotherapy may ‘prime’ the tumour 
microenvironment, and when used in combination 
with immunotherapy may enhance this host anticancer 
immune response. In addition, recent evidence has sug-
gested that moving immunotherapy earlier in the disease 
trajectory when tumour is in situ may improve response 
rates [28]. Given that immune checkpoint blockade acts 
systemically, by using immunotherapy for treatment of 
LARC there is also the potential to reduce distant micro-
metastases. Indeed, this systemic effect of immuno-
therapy may be increased through the combination with 
radiotherapy in what is known as an abscopal effect [29].
The PRIME-RT trial will test the intensification of 
neoadjuvant treatment for patients with LARC using 
immune checkpoint blockade combined with radiother-
apy and chemotherapy. The main aims of the PRIME-RT 
trial are:
a) To test whether the addition of anti-PD1 immuno-
therapy to extended neoadjuvant regimens results 
in high rates of complete response that may enable 
Discussion: PRIME‑RT will explore if adding immunotherapy to neoadjuvant radiotherapy and chemotherapy for 
patients with LARC can prime the tumour microenvironment to improve complete response rates and stoma free 
survival. Sequential biopsies are a key component within the trial design that will provide new knowledge on how the 
tumour microenvironment changes at different time‑points in response to multi‑modality treatment. This expectation 
is that the trial will provide information to test this treatment within a large phase clinical trial.
Trial registration Clinicaltrials.gov NCT04621370 (Registered 9th Nov 2020)
EudraCT number 2019‑001471‑36 (Registered 6th Nov 2020)
Keywords: Rectal, Neoplasm, Chemotherapy, Radiotherapy, Immune‑oncology, Immunotherapy, Clinical trial
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a larger proportion of patients with locally advanced 
rectal cancer to have organ preservation
b) To evaluate the priming effect of adding chemother-
apy and immune checkpoint blockade to patients 
receiving SCRT and those treated with LCRT.
Methods/Design
PRIME-RT is an open label, multi-centre phase II ran-
domised trial with 1:1 allocation between arm A and arm 
B (Fig. 1). The main trial will commence after completion 
of a safety run-in.
Trial interventions
The treatment schema for each arm of PRIME-RT is out-
lined in Fig. 2. Arm A consists of SCRT, followed by up to 
six cycles of FOLFOX chemotherapy. Patients also receive 
concurrent durvalumab (anti-PD-1 immune checkpoint 
inhibitor), commencing in the week prior to radiotherapy 
and continuing until completion of FOLFOX chemother-
apy. In Arm B, patients receive LCRT followed by up to 
four cycles of FOLFOX chemotherapy, alongside concur-
rent durvalumab as for Arm A. LCRT consists of 50  Gy 
delivered to the primary tumour and 45 Gy to the elective 
pelvic nodes, delivered over 25 fractions with concomi-
tant capecitabine chemotherapy 825  mg/m2 orally twice 
daily on the days of radiotherapy. Regarding LCRT, 45 Gy 
in 25 fractions has been the standard, accepted dose in the 
UK for pelvic rectal radiotherapy for many years and was 
used in a recent, large phase III rectal cancer trial (ARIS-
TOTLE), which employed 3D conformal radiotherapy as 
the treatment technique [30]. There is evidence of a dose 
related response for rectal tumours [31], which has led to 
increased interest in using boost doses to areas of primary 
tumour. It is now more feasible to deliver boost doses safely 
and efficiently with the use of intensity modulated radio-
therapy (IMRT). The dose levels used in PRIME-RT align 
with recently published United Kingdom (UK) consensus 
guidance, which has suggested using 45 Gy to elective pel-
vic nodes and a 50 Gy boost to primary tumour [32, 33].
For both arms, FOLFOX consists of a 400 mg/m2 bolus 
of fluorouracil over 10–15 min followed by a 2400 mg/m2 
fluorouracil given as a continuous infusion over 46–48 h 
starting on day 1. Folinic acid 350 mg flat dose is admin-
istered over 2 h, in addition to oxaliplatin 85 mg/m2 over 
2 h, both on day 1. Durvalumab is delivered as 1500 mg 
intravenously over 60 min every four weeks for up to four 
cycles in both arms. Radiotherapy treatment is delivered 
using inverse planned IMRT.
Trial population
The target population for the main PRIME-RT trial con-
sists of adult (≥ 18 years), fit (ECOG Performance Status 
0–1) patients with a LARC which can be encompassed 
within a radical radiotherapy field. One of the follow-
ing disease related features must be present on magnetic 
resonance imaging (MRI) assessment: cT3b+, EMVI 
positive, primary tumour or morphologically malignant 
lymph node at 2 mm or less from the mesorectal fascia 
or beyond the mesorectal fascia or a low rectal tumour 
requiring abdomino-perineal excision (APE). Patients are 
not permitted to enter the trial if they have any degree 
of dihydropyrimidine dehydrogenase deficiency, have 
received previous pelvic radiotherapy or have a history 
of inflammatory bowel disease or active autoimmune 
disease. Systemic steroid therapy or any other form of 
immunosuppressive medication within 14  days prior to 
the first dose of trial treatment is not permitted.
The trial criteria for the safety run-in is identical to 
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Fig. 1 Process of recruitment of patients to PRIME‑RT and random 
allocation of patients between treatment arms
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have metastatic disease with a primary rectal tumour 
in  situ and to have received prior chemotherapy, but 
not immunotherapy, for the current malignancy. Addi-
tional File 1 contains a full list of inclusion and exclu-
sion criteria. Patients for both parts of the trial will be 
recruited in the hospital setting and identified as poten-
tial trial candidates via multi-disciplinary meetings. 
The trial opened on 15th January 2021 with the first 
patient recruited to the safety run-in cohort on 28th 
January 2021.
Radiotherapy 
25 GY in 5 
fracons 
Durvalumab Every 4 Weeks up to 4 cycles
FOLFOX Every 2/52 x 6 cycles
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Fig. 2 Treatment schema for Arm A and Arm B of PRIME‑RT
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Study objectives and end‑points
The principal objective addressed in PRIME-RT is 
whether the addition of durvalumab and FOLFOX chem-
otherapy to radiotherapy in the neoadjuvant setting for 
patients with LARC improves response rates. Specifically, 
the primary endpoint is a measurement of the proportion 
of patients achieving either complete clinical or pathologi-
cal response in each trial arm. Both clinical and pathologi-
cal complete response are included to ensure that patients 
undergoing surgery, as well as those following an organ 
preservation strategy, will both contribute to assess-
ment of the primary endpoint. Clinical response will be 
assessed using a combination of MRI, endoscopic and 
clinical examination as outlined in Additional File 2, with 
the European Society of Gastroenterology and Abdominal 
Radiology (ESGAR) template [34] used for MRI reporting.
Secondary objectives include evaluation of safety and tol-
erability of treatment, including quality of life and surgical 
morbidity. Quality of life will be assessed at baseline and 
months 3, 6, 12, 18, 24 and 30 using three validated ques-
tionnaires (European Organization for Research and Treat-
ment of Cancer Quality of Life Core Questionnaire 30, the 
European Organization for Research and Treatment of 
Cancer Quality of Life Questionnaire-Colorectal Cancer 29 
and the Euro Qol-5 dimensions 3 levels survey). Treatment 
efficacy will be measured using additional secondary end-
points such as the neoadjuvant rectal score (NAR), MRI-
confirmed tumour regression or near tumour regression or 
any degree of down-staging. Longer-term outcomes such 
as overall relapse rates and survival will also be measured.
CD3 + T-lymphocyte concentration is the main trans-
lational end-point for the trial and will be used to inves-
tigate the extent of immune activation within rectal 
biospecimens before, during (week 2 and 6) and after 
treatment. Biopsy assessment of CD3 + will be deter-
mined in tumour tissues by immunohistochemistry and 
divided into two groupings as none/low vs moderate/
high based on previous descriptions [35–37] and treat-
ment will be considered to be effective if a moderate-high 
CD3 + infiltrate is seen in 40% of patients.
Exploratory objectives for the PRIME-RT trial will 
include evaluation of biomarkers of treatment resistance 
and response to immunotherapy-radiotherapy combi-
nations, assessment of the molecular characteristics of 
rectal cancers in which an immune priming response is 
achieved, and an analysis of how these responses may 
differ with respect to MMR status. The schedule for col-
lection of data for the purposes of assessing all trial end-
points is detailed in Additional File 3.
Trial design and analysis plan
Each arm is a single arm phase II study design with its 
own safety run-in [38] and there will be no comparative 
analyses between arms. Permutated block randomisa-
tion will be used for the safety-run in and for the main 
trial a minimisation algorithm incorporating a random 
component will be used to allocate patients (1:1) between 
the arm A and arm B. Stratification will be depend-
ent on whether the tumour is deemed resectable via (a) 
APE or (b) a sphincter-preserving resection (low anterior 
resection).
The safety run-in is being performed to identify any 
significant overlapping toxicities that could potentially 
preclude curative surgery in the main trial. After three 
patients in each arm of the safety run-in have completed 
treatment and been followed up for 30 days, recruitment 
will be postponed to allow a Committee to review all 
adverse event data. If a toxicity signal is detected, a deci-
sion will be made on the appropriateness of de-escalating 
treatment depending on which part of the treatment is 
most likely to be responsible. An additional three patients 
may be added to each arm of the safety run-in depending 
on the toxicity observed. The criteria for cohort expan-
sion are detailed in Additional File 1. An Independent 
Data Monitoring Committee will make the decision on 
whether the randomised phase II component of PRIME-
RT will open.
Analysis plan and sample size calculation
Efficacy analyses will be on an intention to treat basis 
and safety analyses will include all patients who start 
treatment. For the primary efficacy analysis, a one-sided 
80% confidence interval for the proportion of patients 
in each arm who have a complete response will be cal-
culated using the Clopper–Pearson [39] approach. In 
each arm, treatment will be considered effective if at least 
five patients have a complete response. This pre-defined 
end-point for both trial arms is based on a hypothesis 
that complete response rates at six months will exceed 
30% compared to rates of approximately 15% for stand-
ard long course chemoradiotherapy (LCRT) [14, 15]. If 
at least five patients in an arm have a complete response 
rate (equating to a success rate of 23.8%, with a lower 
one-sided 80% confidence limit of 15.1%), the hypoth-
esis that the true efficacy is ≤ 15% is rejected. If the true 
complete response rate is 30% (the hypothesised level of 
efficacy used for the primary endpoint calculation), 21 
patients per arm provides 80% power to demonstrate that 
the one-sided 80% confidence interval (20% 1-sided level 
of statistical significance) for the complete response rate 
excludes 15% (the minimum level of efficacy to warrant 
further evaluation).
If both arms appear to be equally effective, the main 
secondary endpoint (occurrence of Grade 3–5 treatment-
emergent and treatment-related adverse events) will 
be used to determine the most appropriate trial arm to 
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take forward for further study. The null hypothesis is that 
50% of patients will not experience any Grade 3–5 tox-
icity, with an alternative hypothesis that 78% of patients 
will not experience any Grade 3–5 toxicity. If at least 14 
participants in an arm experience no Grade 3–5 toxicity, 
(equating to a no toxicity rate of 66.6%, with a lower one-
sided 90% confidence limit above 50%), the null hypoth-
esis (that the true “no Grade 3–5 toxicity” rate is ≤ 50%) 
will be rejected in favour of the alternative hypothesis 
that the “no Grade 3–5 toxicity” rate is 78%. For the sec-
ondary endpoint calculation, 21 patients per arm pro-
vides 90% power to demonstrate that the one-sided 90% 
confidence interval (10% 1-sided level of statistical signif-
icant) for the “no Grade 3–5 toxicity” rate excludes 50%.
If both trial arms achieve a complete response rate 
of over 30% and demonstrate low toxicity as described 
above, a tiered consideration of other endpoints will be 
used to decide which treatment strategy to use moving 
forwards. In order of decreasing importance, these fac-
tors are; toxicity, absolute percentage of patients with 
complete response, surgical morbidity, the NAR score, 
local regrowth (36 months), overall survival (36 months), 
recurrence free survival (36  months), quality of life, 
percentage of patients with high grade CD3 + or a fold 
change in CD3 + compared to baseline.
Discussion
PRIME-RT is investigating an important clinical question 
about the effectiveness, safety, and tolerability of intensi-
fying LARC neoadjuvant treatment. The number of tri-
als investigating novel strategies to improve responses 
to neoadjuvant treatment and to increase organ preser-
vation rates that reported findings in 2020 [8, 12, 40, 41] 
demonstrates the intense interest in this approach within 
the academic and clinical community. A recent survey of 
patients with rectal cancer in Germany has confirmed 
that treatment intensification to improve organ preserva-
tion rates is also a concept favoured by patients, even at 
the expense of toxicity from multi-modality non-surgical 
treatment [42].
The PRIME-RT trial has the potential to have academic 
and wider impacts. The strong translational component 
to PRIME-RT provides a unique opportunity to analyse 
changes in the immune microenviroment in response to 
treatment and to track how this changes over time. This 
information will help to address the urgent need for bio-
markers of response and resistance that are required by cli-
nicians in order to tailor treatment to the patient in front 
of them in clinic. The radiotherapy protocol for PRIME-RT 
has been largely based on the novel, national IMRT rec-
tal cancer guidance for the UK [32, 33]. Sites recruiting to 
PRIME-RT will have the opportunity to implement this 
new guidance in the context of the PRIME-RT trial and 
to have prospective peer review and quality assurance for 
their radiotherapy volumes and plans. If the effectiveness of 
either of the treatment strategies is proven, this signal will 
be tested in a larger phase trial. It is expected that patients 
within the trial may benefit from an increased rate of com-
plete response and/or a reduction in distant recurrence 
compared to standard care; if tested within a larger trial 
this has the potential to be practice changing and improve 
outcomes on a larger scale. Lastly, this trial is only possi-
ble through collaboration between industry and academia. 
Building these relationships is an important endeavour to 
ensure investment in clinically relevant trials going for-
ward. Two high profile consensus statements on novel drug 
radiotherapy combinations have highlighted five key mes-
sages [43, 44]: (1) the potential of combinations to improve 
outcomes, (2) importance of communication between 
industry, academia, regulatory agencies and patient advo-
cates, (3) intelligent trial design, (4) validated endpoints and 
(5) novel approaches including immune-oncology com-
bined with radiotherapy should be prioritised. PRIME-RT 
is part of new paradigm in the treatment of rectal cancer 
that satisfies all of these key aims.
Complete response rate has been chosen as the primary 
end-point for PRIME-RT because it is a clinically mean-
ingful indicator of treatment efficacy and will allow com-
parison of outcomes from other early phase trials in this 
setting. It must be acknowledged however,  the limitation 
of complete response as an outcome measure is that it is 
not a validated surrogate for longer term outcomes of dis-
ease free (DFS) or overall survival (OS) [45]. An impor-
tant secondary endpoint in PRIME-RT is the NAR score, 
which will be measured for patients who undergo surgi-
cal resection. This score has been validated as a surro-
gate endpoint for predicting OS and DFS in clinical trials 
assessing neoadjuvant treatment for patients with locally 
advanced rectal cancer [45, 46]. Lastly, the main trans-
lational endpoint for PRIME-RT (CD3 + concentration) 
has been chosen based on the consistent observation that 
high density T cells are associated with improved survival 
independent of disease stage and mismatch repair status 
[47–49].
There are other trials in set-up and currently 
recruiting that are investigating the use of neoadju-
vant immune checkpoint blockade for patients with 
LARC. Encouraging results have already been reported 
from the VOLTAGE trial in Japan where 5 cycles of 
nivolumab (anti-PDL1) post LCRT in 41 patients with 
cT3/4 rectal cancer resulted in pathological com-
plete response rates of 30% in pMMR disease (11/37 
patients) and 60% in dMMR disease (3/5 patients) [24]. 
In this study, subgroup analyses suggested improved 
responses were associated assessment of immunologi-
cal biomarkers. PRIME-RT will build on the results of 
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the VOLTAGE trial through measurement of MMR sta-
tus and CD3 + concentration for all patients. In addi-
tion, PRIME-RT holds an important place in the current 
landscape because it is the only study currently investi-
gating both SCRT and LCRT, which is important given 
it is not year clear which option offers optimal down-
staging when combined sequentially with chemother-
apy, or indeed which order [41, 50, 51].
A challenge of any early phase trial combining radio-
therapy with novel therapies is the potential overlap-
ping toxicity from the interventions used. Diarrhoea, in 
particular, is a concern in the PRIME-RT trial because, 
as well as being a symptom of some rectal cancers, it is 
a recognised adverse event from radiotherapy, chemo-
therapy, and immune checkpoint blockade. Reassuring 
results have recently been disseminated for the NRG-
GI-002 trial [52] which investigated the use of pem-
brolizumab (anti-PD1) in combination with LCRT after 
8 cycles of mFOLFOX6 chemotherapy. During LCRT in 
this trial, the rate of grade 3 + adverse events was 48.2% 
for the experimental arm versus 37.3% in the control 
arm. Nevertheless, actions have been taken to address 
concerns regarding toxicity from treatment in PRIME-
RT. First, data from recently reported trials combining 
radiotherapy with chemotherapy alone have been used 
to power the toxicity analysis. Specifically, the expected 
range of Grade 3–5 adverse event rates is 22–50% for 
treatment without durvalumab, based on contempora-
neous clinical trial data from the RAPIDO [8, 53, 54], 
Polish II [55], UNICANCER-PRODIGE 23 [12] and 
CAO/ARO/AIO-12 [46] clinical trials. The issue of over-
lapping toxicity has also be mitigated in PRIME-RT by 
the inclusion of the safety run-in cohort, which will test 
the safety and tolerability of the proposed treatment 
strategy in a small group of patients who are not receiv-
ing treatment with curative intent. If any safety signals 
are detected, adjustments will be made to the PRIME-
RT treatment schedule with the aim of reducing this 
toxicity. Finally, a detailed algorithm has been provided 
within the trial protocol to direct clinicians of the pro-
active measures that should be taken if a patient enrolled 
in PRIME-RT develops diarrhoea (Additional file 2).
Conclusion
PRIME-RT is a translationally rich, phase II parallel arm 
trial treating patients with LARC with total neoadjuvant 
treatment in combination with immune checkpoint block-
ade. The trial will investigate the potential priming ability 
of radiotherapy and chemotherapy to enhance responses 
to immunotherapy with two different radiotherapy frac-
tionation schedules and address several important unan-
swered clinical questions for patients with LARC.
Trial Status
At the time of publication, PRIME-RT was open to 
recruitment in two UK centres. Trial recruitment began 
in January 2021, with the first patient enrolled on 27th 
January 2021, and the estimated recruitment end date is 
June 2022. The current PRIME-RT protocol is Version 2, 
24th September 2020.
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